Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18917080 | PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPION | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18811352 | PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODEL | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18640730 | STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB | April 2024 | June 2025 | Allow | 14 | 3 | 0 | No | No |
| 18637037 | HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAME | April 2024 | January 2025 | Allow | 9 | 1 | 0 | No | No |
| 18618520 | COMPOSITIONS COMPRISING ATICAPRANT | March 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18612370 | CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIA | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18612430 | Formulations Of Apremilast | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18607237 | DEVICE AND METHOD FOR TREATING CANCER | March 2024 | April 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18595026 | USE OF SACCHARIDES FOR CRYOPROTECTION AND RELATED TECHNOLOGY | March 2024 | June 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18590452 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | February 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18582459 | APPLICATOR AND SYSTEM FOR ADMINISTERING AND DISPENSING FLOWABLE PHARMACEUTICAL PREPARATIONS | February 2024 | June 2025 | Allow | 16 | 1 | 0 | No | No |
| 18435245 | PHARMACEUTICAL FORMULATIONS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18415196 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | January 2024 | December 2024 | Allow | 11 | 2 | 0 | No | No |
| 18543759 | NOVEL GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORM | December 2023 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18383648 | 4-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 0 | 1 | No | No |
| 18483007 | TABLET FOR ORAL SUSPENSION | October 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18376038 | SKIN SOLUTION WITH SOLUBILIZED BAKUCHIOL | October 2023 | June 2025 | Allow | 20 | 1 | 0 | No | No |
| 18478524 | ORAL POUCH PRODUCT | September 2023 | December 2024 | Allow | 15 | 3 | 0 | No | No |
| 18243735 | STABLE SOLID FINGOLIMOD DOSAGE FORMS | September 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18456300 | PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODEL | August 2023 | August 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18451030 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | August 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18353323 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | July 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18346115 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS | June 2023 | January 2025 | Allow | 18 | 2 | 0 | No | No |
| 18333785 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | June 2023 | December 2023 | Allow | 6 | 3 | 0 | No | No |
| 18208775 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18321173 | DRUG DELIVERY SYSTEMS AND METHODS FOR MAKING AND USING THE SAME | May 2023 | July 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18196718 | Formulations Of Apremilast | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18315618 | Implantable Device for Sustained Release of a Macromolecular Drug Compound | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18300739 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | April 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18296954 | LIMIT SIZE LIPID NANOPARTICLES AND RELATED METHODS | April 2023 | October 2024 | Allow | 19 | 2 | 0 | No | No |
| 18191910 | TABLET FOR ORAL SUSPENSION | March 2023 | February 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18184443 | Methylphenidate Extended Release Chewable Tablet | March 2023 | January 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18118919 | Concentrated Nutritional or Supplemental Compound for Intestinal, Gut-Brain Axis and Neurobiological Homeostasis through Calibrated Absorption Including Neurotransmitter or Any Equilibrating Compound Release to Treat or Mitigate Disease and Co-morbidities, Particularly Obesity and Malnourishment. | March 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18179093 | COMPOSITIONS COMPRISING ATICAPRANT | March 2023 | May 2024 | Abandon | 15 | 2 | 0 | No | No |
| 18177348 | GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORM | March 2023 | October 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18007247 | NOVEL GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORM | January 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18158128 | HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAME | January 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18157393 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | January 2023 | May 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18154566 | MICRONEEDLE PATCH FOR DELIVERING AN ACTIVE INGREDIENT TO SKIN | January 2023 | June 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18092928 | USE OF SACCHARIDES FOR CRYOPROTECTION AND RELATED TECHNOLOGY | January 2023 | June 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18091481 | STABLE SOLID FINGOLIMOD DOSAGE FORMS | December 2022 | February 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18074996 | Cerium Oxide Nanoparticle Compositions and Methods | December 2022 | June 2025 | Allow | 30 | 3 | 1 | No | No |
| 18074699 | TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS | December 2022 | September 2024 | Allow | 21 | 2 | 0 | No | No |
| 18049136 | COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES | October 2022 | June 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17937525 | METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERS | October 2022 | September 2023 | Allow | 11 | 2 | 1 | No | No |
| 17958678 | TREATMENT OF PAIN BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | October 2022 | September 2023 | Allow | 12 | 3 | 0 | No | No |
| 17952691 | Concentrated Nutritional or Supplemental Compound for Intestinal, Gut-Brain Axis and Neurobiological Homeostasis through Calibrated Absorption Including Neurotransmitter or Any Equilibrating Compound Release to Treat or Mitigate Disease and Co-morbidities, Particularly Obesity and Malnourishment. | September 2022 | August 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17899769 | Formulations Of Apremilast | August 2022 | April 2023 | Allow | 8 | 1 | 0 | No | No |
| 17864632 | EXTENDED RELEASE COMPOSITIONS COMPRISING TRIHEXYPHENIDYL | July 2022 | February 2023 | Allow | 7 | 1 | 0 | No | No |
| 17862854 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE | July 2022 | January 2023 | Abandon | 6 | 1 | 0 | No | No |
| 17790429 | TREATMENT OF PAIN BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | June 2022 | March 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17848685 | COMPOSITIONS FOR DELIVERY OF REBOXETINE | June 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17849426 | DRUG-COATED MEDICAL DEVICES | June 2022 | September 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17840382 | TABLET FOR ORAL SUSPENSION | June 2022 | December 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17750648 | STABLE LOW DIGESTIVE ENZYME CONTENT FORMULATION | May 2022 | March 2025 | Allow | 34 | 1 | 0 | No | No |
| 17747276 | SOLID PREPARATION CONTAINING TAFAMIDIS AND METHOD FOR PRODUCING THE SAME | May 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17698787 | METHOD FOR FABRICATION OF ADDITIVELY MANUFACTURED, SELF-GELLING STRUCTURES AND THEIR USE | March 2022 | December 2023 | Allow | 21 | 3 | 1 | Yes | No |
| 17696997 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | March 2022 | March 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17693830 | FORMULATIONS OF PIMAVANSERIN | March 2022 | May 2022 | Allow | 2 | 1 | 0 | No | No |
| 17641020 | THERAPEUTIC FORMULATIONS AND USES THEREOF | March 2022 | May 2025 | Allow | 38 | 1 | 0 | No | No |
| 17673331 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | February 2022 | September 2024 | Allow | 31 | 5 | 0 | Yes | Yes |
| 17576242 | SOLID TABLET DOSAGE FORM OF RIDINILAZOLE | January 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17573333 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES | January 2022 | September 2023 | Allow | 20 | 1 | 0 | No | No |
| 17624329 | SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFEN | December 2021 | April 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17521974 | Labeled Probe and Methods of Use | November 2021 | September 2024 | Allow | 35 | 1 | 1 | No | No |
| 17602934 | DISPERSIBLE TABLET COMPOSITION | October 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17496234 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE | October 2021 | April 2022 | Allow | 6 | 1 | 0 | No | No |
| 17482672 | EXTENDED RELEASE COMPOSITIONS COMPRISING TRIHEXYPHENIDYL | September 2021 | April 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17437353 | ULTRAFINE IRON OXIDE NANOPARTICLE-BASED MAGNETIC RESONANCE IMAGING T1 CONTRAST AGENT | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17464745 | IN SITU GELLING COMPOSITION AS A PH-SELECTIVE AND MUCOADHESIVE SUSTAINED RELEASE DRUG DELIVERY SYSTEM | September 2021 | March 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17406137 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES | August 2021 | November 2023 | Allow | 27 | 2 | 0 | No | No |
| 17444402 | TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS | August 2021 | May 2024 | Allow | 33 | 2 | 0 | No | Yes |
| 17394059 | Extended Release Methazolamide Formulation | August 2021 | July 2022 | Allow | 11 | 1 | 0 | No | No |
| 17310125 | GERM-REPELLENT BOOK AND FOOD PAPER PACKAGING, AND METHOD OF MANUFACTURE | July 2021 | June 2024 | Allow | 35 | 0 | 1 | No | No |
| 17373906 | METHOD FOR MANUFACTURING MARKER WITH AERATED HYDROGEL | July 2021 | November 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17370778 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | July 2021 | May 2023 | Allow | 22 | 1 | 0 | No | No |
| 17360727 | COMPLEXES OF HYDROTALCITES AND FIBERS | June 2021 | December 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17309557 | COATABLE CORE FOR A MODIFIED RELEASE DRUG FORMULATION | June 2021 | March 2025 | Allow | 46 | 3 | 0 | No | No |
| 17309554 | METHOD OF PRODUCING A DELAYED RELEASE DRUG FORMULATION | June 2021 | March 2025 | Allow | 46 | 4 | 0 | Yes | No |
| 17298624 | ANTIBODY-DRUG CONJUGATES AND USE OF ANTIBODIES FOR DRUG DELIVERY | May 2021 | June 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17326826 | ORAL ADMINISTRATION OF 5-FU IN A GELLING NANOSUSPENSION FOR TARGETED DELIVERY TO TREAT COLORECTAL CANCERS | May 2021 | February 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17321729 | NOVEL PREVENTIVE AND THERAPEUTIC TREATMENT FOR COVID 19 AND ANY OTHER DISEASE CAUSED BY SARS COV 2 | May 2021 | July 2024 | Allow | 38 | 5 | 0 | No | Yes |
| 17320155 | THERAPEUTIC SOLID DOSAGE FORMS | May 2021 | May 2024 | Allow | 36 | 2 | 0 | No | No |
| 17317630 | DUAL RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMBINATION OF A BETA-3 ADRENORECEPTOR AGONIST AND A MUSCARINIC RECEPTOR ANTAGONIST | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17315133 | METHYLPHENIDATE COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | May 2021 | January 2023 | Abandon | 21 | 2 | 0 | No | Yes |
| 17245842 | COMPOSITIONS AND METHODS FOR MEASURING AND EXPANDING BLOOD VOLUME | April 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17290042 | LAXATIVE TABLET | April 2021 | June 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17226848 | PHARMACEUTICAL FORMULATIONS | April 2021 | November 2023 | Allow | 31 | 1 | 0 | No | No |
| 17222239 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE | April 2021 | July 2021 | Allow | 4 | 1 | 0 | No | No |
| 17280986 | TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE | March 2021 | February 2025 | Allow | 46 | 1 | 0 | No | No |
| 17216195 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE RELEASING PROSTAMIDE | March 2021 | August 2024 | Allow | 41 | 4 | 0 | No | No |
| 17213744 | Methylphenidate Extended Release Chewable Tablet | March 2021 | July 2021 | Allow | 4 | 2 | 0 | No | No |
| 17209604 | BONE VOID FILLER PREPARATION SYSTEM | March 2021 | November 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17201142 | Co-Processed Lubricant:MCG for Tablets | March 2021 | November 2023 | Allow | 32 | 1 | 0 | No | No |
| 17275915 | FLUORINATION METHOD | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17272378 | WIPE | March 2021 | May 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17184506 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT | February 2021 | September 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17270573 | NOVEL METHODS | February 2021 | November 2023 | Allow | 33 | 2 | 0 | No | No |
| 17177569 | STABLE SOLID FINGOLIMOD DOSAGE FORMS | February 2021 | June 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17175764 | IN SITU GELLING COMPOSITION AS A PH-SELECTIVE AND MUCOADHESIVE SUSTAINED RELEASE DRUG DELIVERY SYSTEM | February 2021 | January 2022 | Allow | 11 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YOUNG, MICAH PAUL.
With a 35.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner YOUNG, MICAH PAUL works in Art Unit 1618 and has examined 1,051 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner YOUNG, MICAH PAUL's allowance rate of 52.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by YOUNG, MICAH PAUL receive 2.84 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by YOUNG, MICAH PAUL is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +29.2% benefit to allowance rate for applications examined by YOUNG, MICAH PAUL. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 32.8% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 62.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.3% of appeals filed. This is in the 37% percentile among all examiners. Of these withdrawals, 53.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 40.7% are granted (fully or in part). This grant rate is in the 41% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.